Michael Hofstätter becomes Glanbia Nutritionals’ new Director of Premix in a move that looks to better define product positioning and focus in the EMEA region.
A mainstay of the Ireland-based firm since February 2014, Hofstätter is now tasked with leading the development and implementation of premix and optimised nutrient strategies for the company.
“I’m excited to continue making an impact by developing a premix strategy to drive commercial success for the company,” he says.
“Having worked with global customers for seven years it has taught me to be open-minded, having dealt with diverse cultures and a huge variety of food, drink and supplement businesses.”
Expertise & knowledge
Anne Brown, Senior VP of Product Strategy, Bioactives and Premix, adds that Hofstätter’s broad expertise and knowledge of the premix landscape, is “invaluable to achieving our strategic goals.”
Meanwhile over at Sabinsa, Founder and Chair, Dr Muhammed Majeed, has moved to promote Dr Umar Jan to President of European Operations.
An eight-year veteran of the US-based supplement specialists, Dr Jan who was previously the firm’s Resident Director of Sabinsa Europe, is now based in the company’s Europe office in Langen, Germany.
“Dr Jan’s scientific knowledge along with his business experience makes him the ideal member of our team to manage our continued growth throughout the European Union,” said Dr Majeed.
Johnson & Johnson
Finally, Johnson & Johnson’s (J&J) Alex Gorsky, is to relinquish his role as CEO with Joaquin Duato lined up as his replacement, effective from January 3, 2022.
Chairman and Chief Executive Officer of J&J since 2012, Gorsky will now be appointed as a member of the Company’s Board of Directors.
“It has been an honour and privilege to lead this company as Chairman and CEO for nearly a decade, and I am pleased to serve as Executive Chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,” says Gorsky.
“The past decade alone has been transformational for Johnson & Johnson as we dramatically increased investment in R&D, drove some of the most important global advances in healthcare, made significant strategic shifts across the business and delivered record performance.
“The decision to step aside was one of the most difficult of my career as I focus more on my family due to family health reasons.”
CEO position an ‘honour’
Currently J&J’s Vice Chairman of the Executive Committee, Duato is “honoured to serve as Johnson & Johnson’s next CEO.”
“Our Company has an unmatched healthcare platform: we are a global pharmaceutical leader with a robust pipeline of transformational and innovative medicines and our Consumer Health business continues to evolve its portfolio of iconic heritage brands and innovative growth brands.
“As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health.”